دورية أكاديمية
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.
| العنوان: | Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. |
|---|---|
| المؤلفون: | Nooka AK; Department of Hematology/Medical Oncology, Emory University, Atlanta, GA.; Winship Cancer Institute, Atlanta, GA., Shanmugasundaram U; Department of Hematology/Medical Oncology, Emory University, Atlanta, GA., Cheedarla N; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA., Verkerke H; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA., Edara VV; Emory Vaccine Center, Emory University, Atlanta, GA.; Yerkes National Primate Center, Atlanta, GA., Valanparambil R; Emory Vaccine Center, Emory University, Atlanta, GA.; Yerkes National Primate Center, Atlanta, GA., Kaufman JL; Department of Hematology/Medical Oncology, Emory University, Atlanta, GA.; Winship Cancer Institute, Atlanta, GA., Hofmeister CC; Department of Hematology/Medical Oncology, Emory University, Atlanta, GA.; Winship Cancer Institute, Atlanta, GA., Joseph NS; Department of Hematology/Medical Oncology, Emory University, Atlanta, GA.; Winship Cancer Institute, Atlanta, GA., Lonial S; Department of Hematology/Medical Oncology, Emory University, Atlanta, GA.; Winship Cancer Institute, Atlanta, GA., Azeem M; Department of Hematology/Medical Oncology, Emory University, Atlanta, GA., Manalo J; Department of Hematology/Medical Oncology, Emory University, Atlanta, GA., Switchenko JM; Winship Cancer Institute, Atlanta, GA., Chang A; Department of Hematology/Medical Oncology, Emory University, Atlanta, GA.; Winship Cancer Institute, Atlanta, GA., Linderman SL; Emory Vaccine Center, Emory University, Atlanta, GA., Roback JD; Winship Cancer Institute, Atlanta, GA.; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA., Dhodapkar KM; Winship Cancer Institute, Atlanta, GA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA., Ahmed R; Winship Cancer Institute, Atlanta, GA.; Emory Vaccine Center, Emory University, Atlanta, GA., Suthar MS; Emory Vaccine Center, Emory University, Atlanta, GA.; Yerkes National Primate Center, Atlanta, GA.; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA., Neish AS; Winship Cancer Institute, Atlanta, GA.; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA., Dhodapkar MV; Department of Hematology/Medical Oncology, Emory University, Atlanta, GA.; Winship Cancer Institute, Atlanta, GA. |
| المصدر: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Sep 10; Vol. 40 (26), pp. 3057-3064. Date of Electronic Publication: 2022 Mar 08. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2003- : Alexandria, VA : American Society of Clinical Oncology Original Publication: New York, N.Y. : Grune & Stratton, c1983- |
| مواضيع طبية MeSH: | COVID-19*/prevention & control , COVID-19 Vaccines*/adverse effects , Multiple Myeloma*, 2019-nCoV Vaccine mRNA-1273 ; Antibodies, Neutralizing ; Antibodies, Viral ; BNT162 Vaccine ; Humans ; Neutralization Tests ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus ; Vaccination |
| مستخلص: | Purpose: Vaccine-induced neutralizing antibodies (nAbs) play a critical role in protection from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased risk of COVID-19-related mortality and exhibit variable serologic response to the vaccine. The capacity of vaccine-induced antibodies in these patients to neutralize SARS CoV-2 or its variants is not known. Methods: Sera from 238 patients with multiple myeloma (MM) undergoing SARS CoV-2 vaccination were analyzed. Antibodies against the SARS CoV-2 spike receptor-binding domain (RBD) and viral nucleocapsid were measured to detect serologic response to vaccine and environmental exposure to the virus. The capacity of antibodies to neutralize virus was quantified using pseudovirus neutralization assay and live virus neutralization against the initial SARS CoV-2 strain and the B1.617.2 (Delta) variant. Results: Vaccine-induced nAbs are detectable at much lower rates (54%) than estimated in previous seroconversion studies in MM, which did not monitor viral neutralization. In 33% of patients, vaccine-induced antispike RBD antibodies lack detectable neutralizing capacity, including against the B1.617.2 variant. Induction of nAbs is affected by race, disease, and treatment-related factors. Patients receiving mRNA1273 vaccine (Moderna) achieved significantly greater induction of nAbs compared with those receiving BNT162b2 (Pfizer; 67% v 48%, P = .006). Conclusion: These data show that vaccine-induced antibodies in several patients with MM lack detectable virus-neutralizing activity. Vaccine-mediated induction of nAbs is affected by race, disease, vaccine, and treatment characteristics. These data have several implications for the emerging application of booster vaccines in immunocompromised hosts. |
| References: | J Clin Microbiol. 2021 Mar 19;59(4):. (PMID: 33468605) Cell Rep Med. 2020 Jun 23;1(3):100040. (PMID: 32835303) Blood. 2021 Oct 7;138(14):1278-1281. (PMID: 34339501) JAMA Netw Open. 2021 Aug 02;4(8):e2121931. (PMID: 34459907) JAMA. 2021 Apr 6;325(13):1318-1320. (PMID: 33635317) Cancer Cell. 2021 Aug 9;39(8):1031-1033. (PMID: 34331856) Science. 2021 Mar 25;:. (PMID: 33766944) Cancer Cell. 2021 Aug 9;39(8):1028-1030. (PMID: 34242572) N Engl J Med. 2021 Aug 12;385(7):664-666. (PMID: 34233096) Leukemia. 2021 Dec;35(12):3534-3541. (PMID: 34326466) Nat Med. 2021 Jun;27(6):981-984. (PMID: 33795870) Nature. 2021 Aug;596(7870):109-113. (PMID: 34182569) Blood Cancer Discov. 2021 Jan;2(1):9-12. (PMID: 34604788) JCI Insight. 2019 Apr 23;5:. (PMID: 31013254) Blood Cancer Discov. 2021 Sep 13;2(6):568-576. (PMID: 34778797) Blood Adv. 2021 Mar 9;5(5):1535-1539. (PMID: 33683337) Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089) N Engl J Med. 2020 Dec 17;383(25):2427-2438. (PMID: 32991794) Viruses. 2021 Apr 25;13(5):. (PMID: 33922936) JAMA. 2021 May 11;325(18):1896-1898. (PMID: 33739374) Blood Cancer J. 2021 Aug 2;11(8):138. (PMID: 34341335) |
| معلومات مُعتمدة: | U19 AI090023 United States AI NIAID NIH HHS; P51 OD011132 United States OD NIH HHS; P30 CA138292 United States CA NCI NIH HHS; U54 CA260563 United States CA NCI NIH HHS; HHSN272201400004C United States AI NIAID NIH HHS; T32 GM142617 United States GM NIGMS NIH HHS; T32 GM008169 United States GM NIGMS NIH HHS; R01 AR077926 United States AR NIAMS NIH HHS; R35 CA197603 United States CA NCI NIH HHS; R01 CA238471 United States CA NCI NIH HHS |
| المشرفين على المادة: | 0 (Antibodies, Neutralizing) 0 (Antibodies, Viral) 0 (COVID-19 Vaccines) 0 (Spike Glycoprotein, Coronavirus) 0 (spike protein, SARS-CoV-2) EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273) N38TVC63NU (BNT162 Vaccine) |
| تواريخ الأحداث: | Date Created: 20220308 Date Completed: 20220909 Latest Revision: 20221115 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC9462534 |
| DOI: | 10.1200/JCO.21.02257 |
| PMID: | 35259002 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1527-7755 |
|---|---|
| DOI: | 10.1200/JCO.21.02257 |